Forbes May 30, 2024
Robert Hart

Topline

Nestlé is tapping into the lucrative weight loss drug market by catering to customers’ “shifting” nutritional needs, CEO Mark Schneider told CNBC on Thursday, an optimistic pivot from one of the industry’s biggest players in the face of dire early predictions suggesting wildly popular drugs like Ozempic, Mounjaro and Wegovy would take a bite out of the food industry.

Key Facts

Get Forbes Breaking News Text Alerts: We’re launching text message alerts so you’ll always know the biggest stories shaping the day’s headlines. Text “Alerts” to (201) 335-0739 or sign up here.

Crucial Quote

Schneider said new lines and offerings targeting GLP-1 drug users will be an “addition” to the food and drinks industry moving forward, rather than its...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Patient / Consumer, Pharma / Biotech, Provider, Retailer
Walmart Digs Deeper Into Metaverse With Minecraft Partnership
From retail to medicine: a doctor’s journey through burnout and bureaucracy
Amazon and Walmart Go Head-to-Head Over Logistics and AI
Instacart embracing AI in push for nutrition
Unified Commerce: Redefining The Future With AI

Share This Article